Previous studies have shown that the hypothalamic concentrations of β-endorphin (β-EP) and other proopiomelanocortin (POMC)-derived peptides change in the female rat following castration and gonadal steroid replacement. In this study we have measured POMC mRNA by solution hybridization assay in the medial basal hypothalamus (MBH) of ovariectomized rats treated with a regimen of estradiol (E2) that we have previously shown alters brain β-EP peptide content. In addition the effect of progesterone (P) was also studied. In the first experiment the concentration of β-EP and α-melanocyte-stimulating hormone (α-MSH) in the MBH of castrated rats decreased significantly after 3 weeks of E2 treatment compared to castrated unreplaced rats: β-EP decreased from 6.00 ± 0.46 to 4.32 ± 0.38 ng/mg protein and α-MSH decreased from 3.00 ± 0.23 to 2.35 ± 0.15 ng/mg protein (p < 0.05). A similar decrease in peptide content was noted in the anterior hypothalamus/ preoptic area. A parallel reduction in the concentration of POMC mRNA was measured in the MBH of the E2-replaced animals: 1.17 ± 0.14 vs. 0.72 ± 0.08 pg/µg RNA (p < 0.02). In a second study castrated rats were studied after 2 weeks of E2 or E2 plus P treatment. After 2 weeks, POMC peptide levels did not change significantly in the MBH of either the E2- or E2 plus P-treated rats. POMC mRNA, however, was significantly reduced from 1.10 ± 0.10 pg/µg RNA in the unreplaced rats to 0.58 ± 0.05 and 0.61 ± 0.06 pg/µg RNA after E2 or E2 plus P, respectively (p < 0.001). No significant change in the concentration of β-EP or POMC mRNA was noted after 48 h of E2. We conclude that E2 has significant effects on POMC gene expression and peptide levels in the MBH of female rats. The parallel decrease in POMC mRNA and peptide levels and the fact that the changes in gene expression precede the changes in peptide content are consistent with an inhibitory effect of E2 on the biosynthesis of POMC in the MBH under these conditions.

Keywords:
Proopiomelanocortin, Endorphin, α-Melanocyte-stimulating hormone, Hypothalamus, Estradiol, Ovariectomy
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.